• 0 我的购物车

    • Ertapenem sodium 厄他培南钠; L-749345; MK-826,99.09%

    产品编号：Bellancom-13625| CAS NO：153773-82-1| 分子式：C22H24N3NaO7S| 分子量：497.50

    Ertapenem sodium 是一种新型的长效 1-β-甲基碳青霉烯类抗生素，具有很广的抗菌谱，包括常见的需氧菌和厌氧菌以及具有广谱 β-内酰胺酶的生物体。

    本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

    货号 包装 价格 库存与货期 购买量 操作
    Bellancom-13625
    		￥600.00 杭州 北京（现货）
    Bellancom-13625
    		￥1400.00 杭州 北京（现货）
    Bellancom-13625
    		￥2400.00 杭州 北京（现货）

    增值税发票√顺丰快递√订货电话：18601927057

    Ertapenem sodium 厄他培南钠; L-749345; MK-826

    产品介绍 Ertapenem sodium (L-749345) 是一种广谱的长效 β-内酰胺。Ertapenem sodium 对多种厌氧菌具有广谱抗菌活性，其 MIC 值为 0.12 μg/mL。Ertapenem sodium 可用于皮肤、肺、胃、骨盆和泌尿道的细菌感染相关的研究。
    生物活性

    Ertapenem sodium (L-749345) is a broad spectrum and long acting β-lactam antibiotic. Ertapenem sodium has a broad-spectrum anti-anaerobic activity against a variety of anaerobes with a mode MIC of 0.12 μg/mL. Ertapenem sodium can be used for the research of severe infections caused by bacteria in the skin, lungs, stomach, pelvis, and urinary tract.

    体外研究

    Ertapenem sodium (0-100 μg/mL approximately, 48 h) is active against 99.1% of all anaerobes with a mode MIC of 0.12 μg/mL and MIC90 of 1 μg/mL, and MIC’s ≥8 μg/mL for B.fragilis and B.vulgatus species, respectively.

    西域 has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay

    Cell Line: B. fragilis (ATCC 25285), B. thetaiotaomicron (ATCC 29741), and Eubacterium lentum (ATCC 43055)
    Concentration: 0-100 μg/mL approximately
    Incubation Time: 48 h
    Result: Inhibited 99.1% of all isolate with a mode MIC of 0.12 μg/mL and MIC90 of 1 μg/mL, and 98.8% of the isolates were susceptible among the B. fragilis group.
    体内研究
    (In Vivo)

    Ertapenem sodium (Subcutaneous injection, 0-10 mg/kg, 0-120 h after infection, S. aureus thigh tissue infection model) shows > 3 log10 CFU reduction of organism at 10 mg/kg, and maintains the activity with 3.3 and 4.4 log10 CFU eliminated at 2 mg/kg.
    Ertapenem sodium (Subcutaneous injection, 4h after infection, systemic infection model) is active against all gram-positive organisms, and is also active against gram-negative organisms tested with ED50s of <0.25 mg/kg/dose.

    西域 has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: S. aureus thigh tissue infection model (DBA/2 mice)
    Dosage: 0.5,1, 2, 5, 10 mg/kg (given at 2, 6, 10, 24, 48, 72, 96, 120 h)
    Administration: Subcutaneous injection (0.5 mL after infection)
    Result: Displayed > 3 log10 CFU reduction of organism compared to non-antibiotic-treated controls at 10 mg/kg.
    Maintained the activity with 3.3 and 4.4 log10 CFU eliminated at 2 mg/kg.
    Animal Model: Systemic infection model (DBA/2 female mice, viral antibody-free CD-1 female mice)
    Dosage: 0-3 mg/kg approximately
    Administration: Subcutaneous injection (0.5 mL, begin immediately and 4 h after infection)
    Result: Showed activity against all gram-positive organisms, and also ram-negative organisms tested with ED50s of <0.25 mg/kg/dose.
    Animal Model: CD-1 mice, rats
    Dosage: 10 mg/kg approximately
    Administration: Intraperitoneal injection (pharmacokinetic assay)
    Result: Exhibited an AUC0-∞ ranging from 1.8-21.82 μg•hr/mL in tissue in mice following a 10-mg/kg i.p. dose.
    Exhibited slow clearance rate with a t1/2β of 3.2 h, Clp of 0.47 mL/min/kg, AUC0-8 of 284.15 μg•hr/mL.
    体内研究

    Ertapenem sodium (Subcutaneous injection, 0-10 mg/kg, 0-120 h after infection, S. aureus thigh tissue infection model) shows > 3 log10 CFU reduction of organism at 10 mg/kg, and maintains the activity with 3.3 and 4.4 log10 CFU eliminated at 2 mg/kg.
    Ertapenem sodium (Subcutaneous injection, 4h after infection, systemic infection model) is active against all gram-positive organisms, and is also active against gram-negative organisms tested with ED50s of <0.25 mg/kg/dose.

    西域 has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: S. aureus thigh tissue infection model (DBA/2 mice)
    Dosage: 0.5,1, 2, 5, 10 mg/kg (given at 2, 6, 10, 24, 48, 72, 96, 120 h)
    Administration: Subcutaneous injection (0.5 mL after infection)
    Result: Displayed > 3 log10 CFU reduction of organism compared to non-antibiotic-treated controls at 10 mg/kg.
    Maintained the activity with 3.3 and 4.4 log10 CFU eliminated at 2 mg/kg.
    Animal Model: Systemic infection model (DBA/2 female mice, viral antibody-free CD-1 female mice)
    Dosage: 0-3 mg/kg approximately
    Administration: Subcutaneous injection (0.5 mL, begin immediately and 4 h after infection)
    Result: Showed activity against all gram-positive organisms, and also ram-negative organisms tested with ED50s of <0.25 mg/kg/dose.
    Animal Model: CD-1 mice, rats
    Dosage: 10 mg/kg approximately
    Administration: Intraperitoneal injection (pharmacokinetic assay)
    Result: Exhibited an AUC0-∞ ranging from 1.8-21.82 μg•hr/mL in tissue in mice following a 10-mg/kg i.p. dose.
    Exhibited slow clearance rate with a t1/2β of 3.2 h, Clp of 0.47 mL/min/kg, AUC0-8 of 284.15 μg•hr/mL.
    体内研究

    Ertapenem sodium (Subcutaneous injection, 0-10 mg/kg, 0-120 h after infection, S. aureus thigh tissue infection model) shows > 3 log10 CFU reduction of organism at 10 mg/kg, and maintains the activity with 3.3 and 4.4 log10 CFU eliminated at 2 mg/kg.
    Ertapenem sodium (Subcutaneous injection, 4h after infection, systemic infection model) is active against all gram-positive organisms, and is also active against gram-negative organisms tested with ED50s of <0.25 mg/kg/dose.

    西域 has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: S. aureus thigh tissue infection model (DBA/2 mice)
    Dosage: 0.5,1, 2, 5, 10 mg/kg (given at 2, 6, 10, 24, 48, 72, 96, 120 h)
    Administration: Subcutaneous injection (0.5 mL after infection)
    Result: Displayed > 3 log10 CFU reduction of organism compared to non-antibiotic-treated controls at 10 mg/kg.
    Maintained the activity with 3.3 and 4.4 log10 CFU eliminated at 2 mg/kg.
    Animal Model: Systemic infection model (DBA/2 female mice, viral antibody-free CD-1 female mice)
    Dosage: 0-3 mg/kg approximately
    Administration: Subcutaneous injection (0.5 mL, begin immediately and 4 h after infection)
    Result: Showed activity against all gram-positive organisms, and also ram-negative organisms tested with ED50s of <0.25 mg/kg/dose.
    Animal Model: CD-1 mice, rats
    Dosage: 10 mg/kg approximately
    Administration: Intraperitoneal injection (pharmacokinetic assay)
    Result: Exhibited an AUC0-∞ ranging from 1.8-21.82 μg•hr/mL in tissue in mice following a 10-mg/kg i.p. dose.
    Exhibited slow clearance rate with a t1/2β of 3.2 h, Clp of 0.47 mL/min/kg, AUC0-8 of 284.15 μg•hr/mL.
    性状Solid
    溶解性数据
    In Vitro: 

    H2O : 50 mg/mL (100.50 mM; Need ultrasonic)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 2.0101 mL 10.0503 mL 20.1005 mL
    5 mM 0.4020 mL 2.0101 mL 4.0201 mL
    10 mM 0.2010 mL 1.0050 mL 2.0101 mL
    *

    请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

    In Vivo:

    请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

    ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
    分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

    • 1.

      请依序添加每种溶剂： PBS

      Solubility: 100 mg/mL (201.01 mM); Clear solution; Need ultrasonic

    *以上所有助溶剂都可在 西域 网站选购。
    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    参考文献

    相关文档

    化学品安全说明书(MSDS)

    下载MSDS

    质检证书(COA)

    相关产品


    危险品运输编码 NONH for all modes of transport
    1. 物质的识别
    产品名： Ertapenem sodium
    CAS号： 153773-82-1
    制造商/供应商： 西域试剂
    网站：www.hzbp.cn   邮件：13911702513@139.com
    2. 合成/成分数据
    产品名： Ertapenem sodium
    别名： L-749345; MK-826
    分子式：
    分子量： 497.5
    3. 急救措施
    吸入后： 如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
    皮肤接触后： 用大量的水冲洗，移除污染的衣服和鞋子。
    眼睛接触后： 检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
    吞食后： 如果吞食，用大量纯净水漱口；呼叫医生。
    4. 消防措施
    适当的灭火剂： 雾状水，二氧化碳，干粉或泡沫。
    防护设备： 穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。
    5. 泄漏应急处理
    安全防范措施： 封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
    清洁/收集措施： 使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；
    使用酒精擦洗表面和设备除去污渍；
    根据第11条处理被污染的材料。
    6. 处理和储存
    安全处理说明： 避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
    储存： 2-8°C, dry, sealed
    7. 接触控制和个人防护
    呼吸设备： NIOSH / MSHA认可的呼吸器。
    双手保护： 耐化学腐蚀的橡胶手套。
    眼睛防护： 化学安全护目镜。
    8. 稳定性和反应活性
    稳定性： 按照说明存储是稳定的；避免强氧化剂。
    热分解/其他要避免的情况： 避免光和热。
    9. 毒性资料
    急性毒性： 无可用资料。
    主要刺激性影响： 无可用资料。
    在皮肤上： 无可用资料。
    对眼睛： 无可用资料；可能具有刺激性。
    10. 生态资料
    一般注意事项： 无可用资料。
    11. 废弃处置
    按照所在国家，省份，县市和地方的法规处置。
    12. 运输信息
    正确的运输名称： 无
    非危险品运输： 这种物质被视为非危险品运输。
    13. 法规信息
    尚未有针对此产品作出的化学安全性评估。
    14. 其他信息
    这种化学品仅供受过训练的，有经验的研究人员在穿戴适当装备和授权允许的情况下进行操作处理。以上信息基于我们目前的知识被认为是正确的，但只适用于作为有经验人员的指导。请咨询您自己的安全顾问，并遵守当地和国家的安全法规。在任何其他没有被警告的情况下，并不意味着绝对没有危险存在。西域生物技术不承担任何使用这种化学品所造成的损害和责任。2023 西域生物技术版权所有。





    202467-70-7结构式

    202467-70-7

    ~%

    153773-82-1结构式

    153773-82-1
    文献：WO2013/121279 A2, ; Page/Page column 15 ;
    有竞争力的价格

    匹配竞争对手的价格

    极速物流

    效率为先

    技术支持

    专业经验 贴心服务

    现货库存

    50000+库存

    购物指南


    产品搜索功能

    积分规则

    销售条款

    注册新用户

    订购流程

    如何付款


    运费收取标准

    发票制度说明

    支付方式

    企业信息


    人才招聘

    经营资质

    关于我们

    联系我们

    售后服务


    验货需知

    如何办理退换货

    常见热点问题

    法律声明


    版权声明

    免责声明

    反商业贿赂声明

    网站服务协议

    参考资料


    COA 质检证书

    MSDS 安全说明书

    RS 风险术语

    GHS 危险说明

    结构式搜索

    批量搜索


    版权所有  ©  2024  杭州西域标品科技有限公司            备案/许可证编号为：浙ICP备2023002560号-1            浙公网安备： 浙公网安备 33010802013016号

    在线咨询

    服务热线

    13911702513
    18601927057

    微信客服